Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18678068 | 0.95 | LMNA (0.47) | LMNAPOLBALDH1A1USP2SMN1; SMN2 | |
| SCHEMBL5899164 | 0.82 | LMNA (0.46) | LMNAPOLBALDH1A1USP2SMN1; SMN2 | |
| SCHEMBL20969509 | 0.80 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL18269652 | 0.79 | LMNA (0.51) | LMNAPOLBALDH1A1MGLLUSP2 | |
| SCHEMBL18269643 | 0.79 | LMNA (0.51) | LMNAPOLBALDH1A1MGLLUSP2 | |
| SCHEMBL4169862 | 0.79 | LMNA (0.39) | LMNAPOLBALDH1A1USP2SMN1; SMN2 | |
| SCHEMBL6081013 | 0.78 | ALDH1A1 (0.47) | LMNAPOLBALDH1A1MGLLUSP2 | |
| SCHEMBL8349429 | 0.78 | MEN1 (0.48) | ALDH1A1HPGD | |
| SCHEMBL28992208 | 0.77 | LMNA (0.51) | LMNAPOLBALDH1A1USP2SMN1; SMN2 | |
| SCHEMBL16287309 | 0.76 | KMT2A (0.42) | LMNAPOLBALDH1A1USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144848-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-05-12 | — | — | US | disclosed |
| US-20220144848-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-05-12 | — | — | US | disclosed |
| CN-113474348-A | Substituted oxopyridine derivatives | 拜耳公司 | 2021-10-01 | — | — | CN | disclosed |
| WO-2020127504-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020127508-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144848-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | MVD, VASP, SELP | LMNA 1583/4885POLB 235/4885ALDH1A1 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.